Cholesterol levels according to age

Česká verzia

Authors: J. Špinar ¹; O. Ludka ¹; M. Šenkyříková ¹; J. Vítovec ²; L. Špinarová ²; L. Dušek ³
Authors place of work: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; Interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ²; Institut biostatistiky a analýz Lékařské fakulty a Přírodovědecké fakulty MU Brno, přednosta doc. RNDr. Ladislav Dušek, Ph. D. ³
Published in the journal: Vnitř Lék 2009; 55(9): 724-729
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Summary

Cholesterol levels were measured at public places (mostly department stores) from 2005 to 2008. Sampling was conducted at random, from volunteers, without any prior dietary restrictions. In total, 14,539 persons were assessed. We did not find any significant differences between sexes in cholesterol levels (overall median was 5 mmol/l; 4.9 mmol/l in men and 5.1 mmol/l in women). Smaller proportion of women than men had cholesterol levels lower than 5.0 mmol/l (53.0% of men and 45.2% of women). Cholesterol levels raise with age in both sexes, stagnate at a certain point and subsequently decline; we identified a significant difference in this between men and women – the levels start to stagnate at the age of 50 in men and beyond the age of 65–70 years in women. The levels fall with increasing age in both sexes after the age 65 years. Cholesterol levels rise with age in both sexes before the age of 50 years; this trend is the same in both sexes (i.e. there is no significant difference between sexes, p = 0.687). Nevertheless, cholesterol levels are statistically significantly higher in women than in men in the over 55 years age group (the difference in the cholesterol level values median is up to 0.8–0.9 mmol/l). This difference is retained to advanced age of > 75 years.

Key words:
cholesterol – age – gender

Zdroje

1. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): E1–E40.

2. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.

3. Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndroms. N Engl J Med 2004; 350: 1495–1502.

4. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

5. de Lemos JA, Blazing MA, Wiviott SD et al. A to Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–1316.

6. Pedersen TR, Faergeman O, Kastelein JJ et al. Incremental Decrease in End Points Through Aggressive Lipid-Lowering Study Group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2006; 294: 2437–2445.

7. Cannon CP, Steinberg BA, Murphy SA et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438–445.

8. Ridker PM, Danielson E, Fonseca FA et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.

9. Agrinier N, Cournot M, Ferrières J. Dyslipdemia in women after 50: Age, menopause or both. Ann Cardiol Angeiol (Paris) 2008; 58: 159–164.

10. Graff Iversen S, Thelle DS, Hammar N.Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil 2008; 15: 83–88.

11. Skrzypczak M, Szwed A. Assessment of the body mass index and selected physiological parameters in pre- and post menopausal women. Homo 2005; 56: 141–152.

12. Nerbrand C, Lidfeldt J, Nyberg P et al. Serum lipids and lipoproteins in relation to endogenous and exogenous female sex steroids and age. The Women’s Health in the Lund Area (WHILA) study. Maturitas 2004; 48: 161–169.

13. Spinar J, Ludka O, Musil V et al. The profile and prognosis of patients hospitalised with heart failure. The value of discharge blood pressure and cholesterol. Int Heart J 2008; 49: 691–705.

14. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933–1940.

15. Horwich TB, Fonarow GC, Hamilton MA et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216–224.

16. Elliot DC, Wales CE. Low lipid concentration in critical illness: hypercholesterolemia among trauma patients. Crit Care Med 1994; 22: 1437–1439.

17. Gui D, Spada PL, De Gaetano A et al. Hypercholesterolemia and risk of death in the critically ill surgical patients. Intensive Care Med 1996; 22: 790–794.

18. Fraunberger P, Nagel D, Walli AK et al. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med 2000; 28: 3574–3575.

19. Fonarow GC, Horwich TB. Cholesterol and mortality in heart failure. The bad gone good? J Am Coll Cardiol 2003; 42: 1641–1643.

20. Schatz IJ, Masaki K, Yano K et al. Cholesterol and all cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358: 351–355.

21. Manolio TA, Pearson TA, Wenger NK et al. Cholesterol an heart disease in older persons and women. Ann Epidemiol 1992; 2: 161–167.

22. Psaty BM, Furberg CD, Kuller LH et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults. Arch Intern Med 1999; 159: 1339–1347.

23. Akerblom JL, Costa R, Luchsinger JA et al. Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. Age Ageing 2007; 37: 207–213.

24. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti vypracované výborem České společnosti pro aterosklerózu. Cor Vasa 2007; 49: K73–K86.

25. Widimský J jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101–118.

26. Špinar J, Hradec J, Meluzín J et al. Doporučení pro diagnostiku a léčbu srdečního selhání ČKS 2006. Cor Vasa 2007; 49: K5–K33.

27. Špinar J, Sepši M, Ludka O. Registr Brno – Farmakoterapie po infarktu myokardu. Cor Vasa 2009; 51: 128–130.

28. Špinar J, Vítovec J, Souček M et al. CORD investigators CORD. COmparison Of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitř Lék 2009; 55: 481–488.